Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

7.79
-0.0500-0.64%
Post-market: 7.78-0.0103-0.13%19:59 EDT
Volume:7.62M
Turnover:59.32M
Market Cap:8.26B
PE:-7.88
High:7.95
Open:7.85
Low:7.60
Close:7.84
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:0.99
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-7.89
PE(LYR):-20.39

Loading ...

ImmunityBio wins five US patents for ANKTIVA-BCG cancer treatment combo through 2035

Reuters
·
May 18

Immunitybio Inc - Patents Cover Anktiva Plus Bcg for Bladder Cancer With Terms Through at Least 2035

THOMSON REUTERS
·
May 18

ImmunityBio Secures Exclusive Rights to Develop, Commercialize Tokyo-172 BCG in US

MT Newswires Live
·
May 18

ImmunityBio signs exclusive US supply deal with Japan BCG Laboratory for Tokyo BCG strain

Reuters
·
May 17

Immunitybio Signs Exclusive U.S. Agreement With Japan Bcg Laboratory for the Tokyo Strain of Bcg to Enhance Bcg Supply in the United States

THOMSON REUTERS
·
May 17

Press Release: MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

Dow Jones
·
May 15

Stock Track | ImmunityBio Plummets 5.93% Intraday as Q1 Losses Far Exceed Analyst Expectations

Stock Track
·
May 12

Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results

Simply Wall St.
·
May 11

Immunitybio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Stock Track | ImmunityBio Soars 5.61% Intraday on Positive Analyst Coverage and Buy Rating

Stock Track
·
May 09

Immunitybio Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
May 09

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Joint (JYNT) and ImmunityBio (IBRX)

TIPRANKS
·
May 08

ImmunityBio price target lowered to $12 from $13 at BTIG

TIPRANKS
·
May 08

ImmunityBio (IBRX) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 08

ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum

Benzinga Earnings
·
May 08

UPDATE: ImmunityBio Q1 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate

Benzinga Earnings
·
May 07

ImmunityBio faces securities class action after FDA flags misleading promotions; shares fall 21%

Reuters
·
May 07

ImmunityBio Q1 net loss widens to $632.8 million; revenue more than doubled to $44.2 million

Reuters
·
May 07

Immunitybio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7X Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

THOMSON REUTERS
·
May 07

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
May 06